Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28625777

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Eur J Cancer
Publication date
2017 Sep
First author
Gligorov J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Eur J Cancer. 2017 Sep;82:228-229. doi: 10.1016/j.ejca.2017.04.028.
    note
    Source null
    related pmid
    28592381
    relationship
    Comment in

Authors and identifiers

  1. name
    Gligorov J
    type
    Author
  2. name
    Ataseven B
    type
    Author
  3. name
    Verrill M
    type
    Author
  4. name
    De Laurentiis M
    type
    Author
  5. name
    Jung KH
    type
    Author
  6. name
    Azim HA
    type
    Author
  7. name
    Al-Sakaff N
    type
    Author
  8. name
    Lauer S
    type
    Author
  9. name
    Shing M
    type
    Author
  10. name
    Pivot X
    type
    Author
  11. name
    SafeHer Study Group
    type
    CollectiveName
Complete bibliographic record and source provenance
authors
  1. name
    Gligorov J
    type
    Author
  2. name
    Ataseven B
    type
    Author
  3. name
    Verrill M
    type
    Author
  4. name
    De Laurentiis M
    type
    Author
  5. name
    Jung KH
    type
    Author
  6. name
    Azim HA
    type
    Author
  7. name
    Al-Sakaff N
    type
    Author
  8. name
    Lauer S
    type
    Author
  9. name
    Shing M
    type
    Author
  10. name
    Pivot X
    type
    Author
  11. name
    SafeHer Study Group
    type
    CollectiveName
bibliography ids
  1. nci-bib-7df3f5c9ad4cc1417bbd95f1
book metadata
content sha256
30562dc5862d14cd50f48192c6da7b0dd7c82d86d89205db70122c0b75eb0b34
document type
citation
dois
  1. 10.1016/j.ejca.2017.05.010
electronic publication date
display
2017 Jun 16
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28625777
immutable id
pubmed:28625777@30562dc5862d14cd50f48192c6da7b0dd7c82d86d89205db70122c0b75eb0b34
journal
abbreviation
Eur J Cancer
issn electronic
1879-0852
issn print
0959-8049
issue
Source null
name
European journal of cancer (Oxford, England : 1990)
nlm unique id
9005373
pages
237-246
volume
82
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Eur J Cancer. 2017 Sep;82:228-229. doi: 10.1016/j.ejca.2017.04.028.
    note
    Source null
    related pmid
    28592381
    relationship
    Comment in
outcomes validated
false
pmid
28625777
provenance
batch id
1c173f0e18be0c6d461b
provider
NCBI PubMed ESummary
record sha256
11d3f56c481f3fb84ddad031b17ce5c6bbab38dad136804a2eea4e8d096559e0
response sha256
27a6f8bb5d49a8d376b07e1b1768913c558986bf73de92cdd65c8f05a5fa1e61
retrieved at
2026-09-09T23:47:25.975513+00:00
publication date
display
2017 Sep
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28625777/
title
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Preserved source evidence · Not medical advice